Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4321 - Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: a matched cohort study


28 Sep 2019


Poster Display session 1


Psychosocial Aspects of Cancer

Tumour Site



Annelies Boekhout


Annals of Oncology (2019) 30 (suppl_5): v667-v670. 10.1093/annonc/mdz262


A.H. Boekhout1, A. Rogiers2, K. Jozwiak3, M.J. Boers-Sonderen4, A.J.M. van den Eertwegh5, G.A. Hospers6, J.W. de Groot7, M.J.B. Aarts8, E. Kapiteijn9, A.J. Ten Tije10, D. Piersma11, G. Vreugdenhil12, A.A.M. Van der Veldt13, K.P.M. Suijkerbuijk14, E.A. Rozeman15, B. Neyns16, K.J. Janssen17, L.V. van de Poll-Franse18, C.U. Blank19

Author affiliations

  • 1 Psychosocial Research And Epidemiology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 2 Psychiatry, Centre Hospitalier Universitaire Brugmann, Brussels/BE
  • 3 Department Of Epidemiology And Biostatistics, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 4 Medical Oncology, Radboud University Medical Centre, Nijmegen/NL
  • 5 Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, 1081 HV - Amsterdam/NL
  • 6 Medical Oncology, University Medical Centre Groningen, Groningen/NL
  • 7 Medical Oncology, Isala Clinics, Zwolle/NL
  • 8 Medical Oncology, Atrium Medisch Centrum, 6221 JK - Maastricht/NL
  • 9 Medical Oncology, Leids Universitair Medisch Centrum (LUMC), 2333 ZA - Leiden/NL
  • 10 Medical Oncology, Amphia Ziekenhuis-location Molengracht, 4818 CK - Breda/NL
  • 11 Medical Oncology, Medisch Spectrum Twente (MST) - Radiological Examination (only), 7513 ER - Enschede/NL
  • 12 Internal Medicine, Maxima Medisch Centrum -Veldhoven, 5500 MB - Veldhoven/NL
  • 13 Medical Oncology, Erasmus University Medical Center, 3015 CE - Rotterdam/NL
  • 14 Medical Oncology, University Hospital Utrecht, 3508 GA - Utrecht/NL
  • 15 Medical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 16 Department Of Medical Oncology, Universitair Ziekenhuis, 1090 - Brussels/BE
  • 17 Bristol-myers Squibb, Bristol-Myers Squibb, 3528 BD - Utrecht/NL
  • 18 Department Of Psychosocial Studies And Epidemiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam/NL
  • 19 Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4321


Since the introduction of immune-checkpoint blockade, the overall survival has significantly improved for patients with advanced melanoma. However, to date, there is limited data on patients’ functioning and health-related quality of life (HRQoL), years after active treatment. Therefore, we evaluated these outcomes in advanced melanoma survivors (AMS) and compared these with matched controls.


Ipilimumab-treated AMS without systemic treatment for at least 2 years were recruited from 15 hospitals. The primary outcome was HRQoL assessed with the European Organization for Research and Treatment of Cancer quality of life questionnaire-C30 (QLQ-C30). Secondary outcomes were fatigue, anxiety, depression and disease specific HRQoL. Up to 5 controls per AMS were individually matched on age, gender and educational status. Survivors and controls were compared on QLQ-C30 scores using generalized estimating equations. Differences in QLQ-C30 scores were classified as clinically important according to published guidelines.


A total of 89 AMS were evaluated in this study. After last administration of ipilimumab, the mean follow-up (FU) was 45.5 (SD 20.8) months. Comparison with matched controls showed that AMS scored significantly lower on physical (difference (diff) = -5.80, p=.005), role (diff =-5.97, p=.02), cognitive (diff = -8.05, p=.001), and social functioning (diff = -8.49, p = <.001) and higher in symptom burden of fatigue (diff =7.48, p=.004), dyspnea (diff = 6.47, p=.02), diarrhea (diff = 3.78, p=.04) and financial impact (diff = 8.07, p=.001). Comparison between AMS with a FU ≥ 36 and FU < 36 months showed that social functioning, global QoL and financial impact scores were higher among the longer term survivors. Group differences in both analyses were clinically relevant.


Compared to matched controls, AMS showed overall worse functioning scores and more symptoms of fatigue, dyspnea, diarrhea and financial impact. AMS with a longer FU reported better QoL, but more financial issues. These study results may help to develop interventions to the individual healthcare needs of AMS and contribute to the development of appropriate survivorship care.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Netherlands Cancer Institute.


Bristol-Myers Squibb.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.